Tofacitinib monotherapy as maintenance treatment in juvenile dermatomyositis: a case report
Juvenile dermatomyositis (JDM) is a multisystem autoimmune disease associated with considerable morbidity and mortality, having a significant impact on patient health. Early diagnosis and appropriate treatment play a key role in optimising outcomes. JDM management remains challenging, particularly i...
Saved in:
| Main Authors: | Enrique Calvo-Aranda, Delia Argüelles Balas, Estefanía Barral Mena, M Ángeles Martín Díaz |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-05-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/11/2/e005651.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Successful treatment of an anti-MDA5 antibody-positive Juvenile Dermatomyositis patient with refractory interstitial lung disease using tofacitinib
by: Valentina Natoli, et al.
Published: (2025-02-01) -
Treatment and Clinical Outcome of Juvenile Dermatomyositis
by: Chih-Hsing Hung
Published: (2015-02-01) -
Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index
by: Carine Wouters, et al.
Published: (2024-02-01) -
Tacrolimus in refractory juvenile dermatomyositis: Case report and review of literature
by: Anand Prahalad Rao, et al.
Published: (2020-01-01) -
Case report: Successful treatment of anti‐MDA5‐positive to negative dermatomyositis‐associated interstitial lung disease with the JAK inhibitor tofacitinib
by: Zong Jiang, et al.
Published: (2023-06-01)